Loading...
Loading...
ABEO| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.7M |
| Gross Profit | -1.7M |
| Operating Expense | 17.9M |
| Operating I/L | -17.9M |
| Other Income/Expense | 25.3M |
| Interest Income | 1.2M |
| Pretax | 7.4M |
| Income Tax Expense | -1.7M |
| Net Income/Loss | 7.4M |
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in gene and cell therapies for rare genetic diseases. The company's lead program, EB-101, is a gene-corrected cell therapy in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. Additionally, Abeona develops AAV-based gene therapies for Sanfilippo syndrome type A, CLN3 disease, cystic fibrosis, and genetic eye disorders. The company also focuses on AAV-based gene therapy through its AIM vector platform programs, aiming to address unmet medical needs in the market.
